Ironwood Pharmaceuticals

FDA approves Ironwood’s duzallo for gout

Thursday, August 24, 2017

Ironwood Pharmaceuticals announced DUZALLO was approved by the FDA as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. DUZALLO is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects DUZALLO to be commercially available early in the fourth quarter of 2017.

[Read More]

FDA approves Ironwood’s Duzallo for hyperuricemia related to gout

Tuesday, August 22, 2017

Ironwood Pharmaceuticals announced Duzallo was approved by the FDA as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects Duzallo to be commercially available early in the fourth quarter of 2017.

[Read More]

Ironwood Pharmaceuticals adds Amy Schulman to board of directors

Thursday, January 5, 2017

Ironwood Pharmaceuticals has announced the appointment of Amy Schulman to its board of directors. Schulman is an accomplished leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations. She currently holds key leadership roles at two biotech companies, serving as chief executive officer and co-founder of Lyndra and executive chair of SQZ Biotech. In addition, she is a venture partner at Polaris Partners, serving on the firm’s life sciences investment team.

[Read More]

Almirall’s Constella approved in Europe for IBS-C

Wednesday, November 28, 2012

The European Commission has granted marketing authorization to Almirall’s Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.

[Read More]